Antiangiogenic approach in soft-tissue sarcomas

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737140.2013.820579PMID 23944712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience

  2013cited by this paper
• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

  2012cited by this paper
• Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour

  2012cited by this paper
• Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).

  2012cited by this paper
• Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

  2012cited by this paper
• Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

  2012cited by this paper
• Sunitinib malate in solitary fibrous tumor (SFT).

  2012cited by this paper
• Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).

  2012cited by this paper
• Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome.

  2012cited by this paper
• Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas

  2012cited by this paper
• Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.

  2012cited by this paper
• Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

  2011cited by this paper
• Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up.

  2011cited by this paper
• Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

  2011cited by this paper
• Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

  2011cited by this paper
• Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.

  2011cited by this paper
• Treatment of Disseminated Classic Type of Kaposi's Sarcoma with Paclitaxel

  2011cited by this paper
• Trends in survival for patients with metastatic soft‐tissue sarcoma

  2011cited by this paper
• Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma

  2011cited by this paper
• Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.

  2011cited by this paper
• Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis

  2010cited by this paper
• Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.

  2010cited by this paper
• Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

  2009cited by this paper
• Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

  2009cited by this paper
• Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma.

  2009cited by this paper
• Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway

  2009cited by this paper
• Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

  2009cited by this paper
• Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  2009cited by this paper
• Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

  2009cited by this paper
• Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases

  2009cited by this paper
• In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines.

  2008cited by this paper
• Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

  2008cited by this paper
• Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases

  2008cited by this paper
• Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells

  2008cited by this paper
• Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

  2008cited by this paper
• Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.

  2008cited by this paper
• A Kaposi's sarcoma complete clinical response after sorafenib administration.

  2008cited by this paper
• Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling

  2008cited by this paper
• Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

  2007cited by this paper
• Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.

  2007cited by this paper
• A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

  2007cited by this paper
• Expression of hypoxia-inducible factor (HIF)-1α as a biomarker of outcome in soft-tissue sarcomas

  2006cited by this paper
• Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.

  2006cited by this paper
• Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas.

  2006cited by this paper
• Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.

  2006cited by this paper
• Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

  2005cited by this paper
• Thalidomide Inhibits the Growth and Progression of Hepatic Epithelioid Hemangioendothelioma

  2005cited by this paper
• Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

  2005cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• High interstitial fluid pressure — an obstacle in cancer therapy

  2004cited by this paper
• Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma

  2004cited by this paper
• Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma

  2003cited by this paper
• VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition.

  2002cited by this paper
• Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.

  2002cited by this paper
• Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.

  2002cited by this paper
• A role for survivin in chemoresistance of endothelial cells mediated by VEGF

  2002cited by this paper
• Vascular Endothelial Growth Factor and Soft Tissue Sarcomas: Tumor Expression Correlates With Grade

  2001cited by this paper
• Expression of vascular endothelial growth factor in thoracic sarcomas.

  2001cited by this paper
• Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face

  1999cited by this paper
• Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

  1999cited by this paper
• Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma

  1999cited by this paper
• The microtubule-affecting drug paclitaxel has antiangiogenic activity.

  1996cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper

• First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial

  2024cites this paper
• Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report.

  2019cites this paper
• Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma

  2018cites this paper
• Clinicopathological implications of VEGF / VEGFR 2 expression and microvessel density in soft tissue sarcoma

  2017cites this paper
• Combination of cytotoxic agents and targeted therapy for the treatment of advanced sarcomas: preclinical background and early clinical development

  2016cites this paper
• Pazopanib: a novel treatment option for aggressive fibromatosis

  2016cites this paper
• High‐grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging

  2016cites this paper
• Contrast‐Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy in Soft Tissue Sarcomas

  2015cites this paper
• Anti-angiogenic therapy, a new player in the field of sarcoma treatment.

  2014cites this paper
• Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis

  2013cites this paper